FDA Approves Teva's Generic Depo-Medrol Injection

The FDA has granted final approval for Teva Pharmaceutical's abbreviated new drug application for methylprednisolone acetate injectable suspension, 40 mg/mL and 80 mg/mL in single-dose vials.

The Teva product is the AP-rated generic equivalent of Pfizer's Depo-Medrol injection, an anti-inflammatory glucocorticoid for intramuscular, intrasynovial, soft tissue or intralesional injection.

The brand product has annual sales of approximately $41 million.